» Articles » PMID: 38819148

Genotypic Diversity, Virulence, and Molecular Genetic Tools in

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Histoplasmosis is arguably the most common fungal respiratory infection worldwide, with hundreds of thousands of new infections occurring annually in the United States alone. The infection can progress in the lung or disseminate to visceral organs and can be difficult to treat with antifungal drugs. , the causative agent of the disease, is a pathogenic fungus that causes life-threatening lung infections and is globally distributed. The fungus has the ability to germinate from conidia into either hyphal (mold) or yeast form, depending on the environmental temperature. This transition also regulates virulence. and histoplasmosis have been classified as being of emergent importance, and in 2022, the World Health Organization included as 1 of the 19 most concerning human fungal pathogens. In this review, we synthesize the current understanding of the ecological niche, evolutionary history, and virulence strategies of . We also describe general patterns of the symptomatology and epidemiology of histoplasmosis. We underscore areas where research is sorely needed and highlight research avenues that have been productive.

References
1.
Casadevall A . Fungal Diseases in the 21st Century: The Near and Far Horizons. Pathog Immun. 2018; 3(2):183-196. PMC: 6241320. DOI: 10.20411/pai.v3i2.249. View

2.
Isaac D, Berkes C, English B, Hocking Murray D, Lee Y, Coady A . Macrophage cell death and transcriptional response are actively triggered by the fungal virulence factor Cbp1 during H. capsulatum infection. Mol Microbiol. 2015; 98(5):910-929. PMC: 5002445. DOI: 10.1111/mmi.13168. View

3.
Glass N, Kuldau G . Mating type and vegetative incompatibility in filamentous ascomycetes. Annu Rev Phytopathol. 1992; 30:201-24. DOI: 10.1146/annurev.py.30.090192.001221. View

4.
Graybill J . Histoplasmosis and AIDS. J Infect Dis. 1988; 158(3):623-6. DOI: 10.1093/infdis/158.3.623. View

5.
Goughenour K, Rappleye C . Antifungal therapeutics for dimorphic fungal pathogens. Virulence. 2016; 8(2):211-221. PMC: 5354166. DOI: 10.1080/21505594.2016.1235653. View